Changes in natriuretic peptide levels following patiromer-enabled optimization of medical therapy in heart failure: A post hoc analysis of the DIAMOND study.
Kalogeropoulos AP, Hameed I, Anker SD, Bayes-Genis A, Böhm M, Budden J, Cleland JGF, Coats AJS, Ezekowitz JA, Filippatos G, Goudev A, Khan MS, Lindenfeld J, Lund LH, Merkely B, Mentz RJ, Metra M, Moutchia J, Perrin A, Ponikowski P, Priest EL, Rossignol P, Senni M, Shaver C, Waechter S, Weir MR, Pitt B, Butler J.
Kalogeropoulos AP, et al.
Eur J Heart Fail. 2025 Jul 3. doi: 10.1002/ejhf.3754. Online ahead of print.
Eur J Heart Fail. 2025.
PMID: 40607983
In this post-hoc analysis, we evaluated the effect of patiromer-enabled RAASi optimization on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, an established surrogate endpoint for clinical outcomes in HFrEF. ...
In this post-hoc analysis, we evaluated the effect of patiromer-enabled RAASi optimization on N-terminal pro-B-type natriuretic pepti …